MedTrace Logo

Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

NCT00223938 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2021-06-24

No results posted yet for this study

Summary

This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin.

Conditions

Interventions

DRUG

Oral Iron

Oral Iron

DRUG

sodium ferric gluconate

weekly intravenous injection Dose 1

DRUG

sodium ferric gluconate

weekly intravenous injection Dose 2

Sponsors & Collaborators

Principal Investigators

  • Gary Hoel, RPh, PhD · Watson Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-30
Primary Completion
2007-04-27
Completion
2007-04-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00223938 on ClinicalTrials.gov